Business
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs SAN FRANCISCO, June 10,
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs\nSAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress. The meeting is being held from June 9-12, 2022 in Vienna, Austria and virtually. Poster and presentation details are included below: Title: A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies Authors: Anthony Mato, Alexey Danilov, Manish R. Patel, Michael Tees, Ian Flinn, Weiyun Ai, Krish Patel, Michael Wang, Susan O’Brien, Srinand Nandakumar, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, William G. WierdaSession: Chronic lymphocytic leukemia and related disorders - ClinicalAbstract: P649Time: June 10, 16:30 - 17:45 CESTTitle: A First-in-Human Phase 1 Trial of NX-5948, an Oral BTK Degrader, in Patients with Relapsed and Refractory B-cell MalignanciesAuthors: Kim Linton, Graham P. Collins, Dima El-Sharkawi, Rogier Mous, Francesco Forconi, May Tan, Srinand Nandakumar, Erin Meredith, Katherine L. Jameson, Sarah G. Injac, and Jeanette DoorduijnSession: Chronic lymphocytic leukemia and related disorders - ClinicalAbstract: P650Time: June 10, 16:30 - 17:45 CESTAbstracts can be found on the EHA website at: ehaweb.org. Posters will be available for registered attendees for on-demand viewing on the EHA website starting Friday, June 10, 2022 (09:00 CEST). They will also be available on the Events and Presentations page of the Investors section of Nurix’s website. About NX-2127NX-2127 is a novel bifunctional molecule that degrades Bruton’s tyrosine kinase (BTK) and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1a/1b clinical trial in patients with relapsed or refractory B cell malignancies. Initial data from the Phase 1a dose-escalation portion of the study demonstrated clinically meaningful degradation of BTK in ...